Search Results
Your search for 3 matches 14920 pages
Showing 501 - 550Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, 2024, ponatinib (Iclusig) was granted accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).1 Ponatinib is a multitargeted kinase inhibitor. Supporting Efficacy Data and How It Is Used Approval ...
Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, the anti-CD22 monoclonal antibody inotuzumab ozogamicin (Besponsa), which is bound to a toxic natural calicheamicin, was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting...
CAR T-Cell Therapy in Refractory Follicular Lymphoma
On May 15, 2024, lisocabtagene maraleucel (Breyanzi) was granted accelerated approval for adults with relapsed or refractory follicular lymphoma with two or more prior lines of systemic therapy.1 The agent is a CD19-directed genetically modified autologous T-cell immunotherapy. Supporting Efficacy...
Hypofractionated vs Conventionally Fractionated Radiation After Implant-Based Breast Reconstruction
In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated...
Disparities in Exposure to Tobacco Content on Streaming Platforms
The risk of encountering tobacco products being advertised, marketed, or promoted on streaming services based on race, ethnicity, socioeconomic status, and smoking habits was identified in a recent study published by Onyeaka et al in JAMA Network Open. Background The World Health Organization...
Early Interventions May Improve Long-Term Academic Achievement in Pediatric Brain Tumor Survivors
Investigators have found that providing early developmental resources may help reduce the adverse effects of brain tumors and cancer therapy on the academic achievement of young pediatric cancer survivors, according to a recent study published by Somekh et al in the Journal of the National Cancer...
Inoperable Stage III NSCLC: Adaptive Radiotherapy Based on FDG-PET Tumor Residual Uptake
In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard...
BTK Degraders and CELMoDs: Novel Mechanisms Overcoming Resistance in Hematologic Malignancies
Despite advances in targeted therapies for hematologic malignancies, drug resistance and persistent side effects continue to challenge clinicians and limit patient outcomes, underscoring the urgent need for novel therapeutic approaches. At the 2024 Pan Pacific Lymphoma Conference, Marc S. Hoffmann, ...
Menin Inhibitor in KMT2A-Rearranged Relapsed or Refractory Acute Leukemia
In a phase I/II study (AUGMENT-101) reported in the Journal of Clinical Oncology, Issa et al found that revumenib, an oral small-molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, was active in patients with KMT2A-rearranged (KMT2A) relapsed or refractory acute...
Advanced Biliary Tract Cancers: Bevacizumab/Erlotinib Maintenance vs Active Surveillance
In an Indian phase II trial (BEER BTC) reported in the Journal of Clinical Oncology, Ramaswamy et al found that maintenance therapy with bevacizumab/erlotinib improved progression-free survival vs active surveillance in patients with advanced biliary tract cancers who had at least stable disease...
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the...
AI May Help Uncover Relationship Between Radiation Therapy for NSCLC and Cardiac Arrhythmia
Artificial intelligence (AI) tools may be used to better understand the risk of specific cardiac arrhythmias when various parts of the heart are exposed to different thresholds of radiation as part of a treatment plan for non–small cell lung cancer (NSCLC), according to a recent study published by...
Metastatic Pancreatic Adenocarcinoma: Addition of Devimistat to mFFX
As reported in the Journal of Clinical Oncology, Philip et al found that the phase III AVENGER 500 study showed no overall survival benefit with devimistat plus modified fluorouracil, oxaliplatin, irinotecan, and leucovorin (mFFX) vs FFX in patients with metastatic pancreatic adenocarcinoma. As...
Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the...
ASCO Guideline Update Highlights the Importance of Early Integration of Palliative Care for Patients With Cancer
Growing awareness of the benefits of palliative care in patients with cancer has prompted ASCO to update its recommendations for clinicians, patients, caregivers, and health-care organizations on integrating palliative care in oncology.1 The updated guideline reinforces prior recommendations in the ...
Exercise Program May Improve Symptoms, Quality of Life in Patients With Metastatic Breast Cancer
Researchers have shown that participating in an exercise program may improve pain, fatigue, and the quality of life in patients with metastatic breast cancer, according to a recent study published by Hiensch et al in Nature Medicine. Background “Although there’s substantial evidence for the...
An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate
At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered...
LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer
A subgroup analysis of data from the LIBRETTO-431 trial (ClinicalTrials.gov identifier NCT04194944) showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in East Asian patients diagnosed with RET fusion–positive...
Detecting Residual Disease After Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
Although esophageal cancer in the United States is relatively rare, affecting about 22,400 people each year and making up about 1% of all cancer cases,1 the disease is common in East and Central Asia countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous...
Gift of Truth: Reflections on a Father’s Cancer Journey
It was a hot and humid Tuesday in July, and I distinctly remember being grateful for the air conditioning in the pastel-shaded waiting room of the oncology outpatient clinic. My father sat silently beside me. We knew this room well, as we did the doctor we had arrived to see. He had been my...
Age Is Just a Number: Treatment Considerations for Endometrial Cancer in Older Women
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored by two speakers at the 2024 Pan Pacific Lymphoma Conference, sponsored by the University of...
FDA Approves Neoadjuvant/Adjuvant Durvalumab for Resectable NSCLC
The U.S. Food and Drug Administration (FDA) has approved the PD-L1 inhibitor durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive)...
Mouthwash-Based Test May Help Predict Head and Neck Cancer Recurrence
Researchers have examined whether a mouthwash-based test could detect biomarkers to help physicians predict disease recurrence in patients with head and neck cancer, according to a recent study published by Franzmann et al in JAMA Otolaryngology–Head & Neck Surgery. Background Head and neck...
Recurrent or Advanced Endometrial Cancer: Atezolizumab Plus Chemotherapy
As reported in The Lancet Oncology by Nicoletta Colombo, MD, and colleagues, the phase III AtTEnd trial showed improved progression-free survival with the addition of atezolizumab to chemotherapy in patients with recurrent or advanced endometrial cancer, particularly among those with mismatch...
Completion Axillary Lymph Node Dissection to Select Adjuvant Treatment in Breast Cancer and Associated Impairment of Arm Function
In an analysis involving the phase III SENOMAC trial reported in The Lancet Oncology, de Boniface et al found that the use of completion axillary lymph node dissection (cALND) to identify pN2-3 status (at least four nodal metastases) in patients with breast cancer, and thus qualification for...
Efficacy of ‘Symptom-Triggered Testing’ for Detection of Ovarian Cancer
“Symptom-triggered testing”—prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat—detected early-stage aggressive ovarian cancer in one of four individuals affected, according to an analysis from the ROCkeTS trial published by Kwong et al in the ...
Combination Immunotherapies May Boost T-Cell Responses in Patients With Melanoma
Researchers may have uncovered how combination immunotherapies targeting the immune checkpoints PD-1 and LAG-3 may work together to activate immune responses in patients with melanoma, according to two recent studies published by Cillo et al and Andrews et al in Cell. The findings may shed light on ...
Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?
With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission. “Stopping tyrosine kinase inhibitor therapy is something we get a...
T-DXd in HER2-Positive Advanced Colorectal Cancer
As reported in The Lancet Oncology by Kanwal Raghav, MD, and colleagues, the phase II DESTINY-CRC02 trial has identified the preferred dosage of single-agent fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive advanced colorectal cancer. Study Details In the international study, ...
Resected Melanoma: Subsequent Systemic Therapy After Recurrence on Adjuvant Nivolumab
In an analysis from the phase III CheckMate 238 trial reported in the Journal of Clinical Oncology, Jeffrey Weber, MD, PhD, and colleagues found that progression-free and overall survival were improved with subsequent systemic therapy following late vs early recurrence with adjuvant nivolumab in...
Advanced GIST: Long-Term Outcomes With Discontinuation vs Continuation of Imatinib
In a long-term follow-up of a French phase III trial (BFR14) reported in The Lancet Oncology, Jean-Yves Blay, MD, and colleagues found that discontinuation of imatinib in patients with advanced gastrointestinal stromal tumors (GIST) with at least stable disease was associated with markedly poorer...
Association of Regular Aspirin Use With Colorectal Cancer Risk According to Lifestyle Factors
In a study reported in JAMA Oncology, Sikavi et al found that regular aspirin use was associated with a reduced risk of colorectal cancer overall and among individuals with less healthy vs more healthy lifestyles. Study Details The prospective cohort study focused on data from 107,655 participants...
Metastasis-Directed Radiation Therapy Plus Chemotherapy in Oligometastatic Pancreatic Cancer
Researchers have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy may improve progression-free survival in patients with oligometastatic pancreatic cancer, according to a recent study published by Ludmir et al in the Journal of Clinical Oncology and...
Can Neoadjuvant Atezolizumab Set a New Standard for Unresectable Stage III NSCLC?
Immune checkpoint inhibitors, including atezolizumab, have been evaluated in several phase II trials for neoadjuvant therapy in resectable lung cancer, both with and without chemotherapy, such as the LCMC3 trial and CheckMate 816. Ongoing studies, including the IMpower030 trial, are further...
Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III CROWN Trial
In an article in the Journal of Clinical Oncology, corresponding author Benjamin J. Solomon, MBBS, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues provided a long-term analysis of 5-year outcomes from the phase III CROWN trial.1 Median progression-free survival had not been...
Cancer of Unknown Primary: Molecularly Guided Therapy After Disease Control on Platinum-Based Chemotherapy
In the phase II CUPISCO trial reported in The Lancet, Krämer et al found that molecularly guided therapy in patients with unfavorable nonsquamous cancer of unknown primary who had disease control on first-line platinum-based therapy resulted in better progression-free survival vs patients who...
Efficacy of a JAK2/mTOR Inhibitor Combination in Controlling Acute Graft-vs-Host Disease
Adding a Janus kinase 2 (JAK2) inhibitor to standard immunosuppressive drugs may not improve prevention of acute graft-vs-host disease in patients with hematologic malignancies undergoing treatment with allogeneic hematopoietic cell transplantation, according to a recent study published by Pidala...
Physician Community Comes Together to Urge Congress to Act on Medicare Payment Reform
ASCO, along with more than 100 medical organizations and societies, sent a letter to members of the U.S. House and Senate leadership urging Congress to prioritize and advance several bills and legislative proposals that would provide greater fiscal stability for physicians and reform key elements...
Metastatic NSCLC Survival Rates in the Immunotherapy Era
The survival rates of patients with advanced non–small cell lung cancer (NSCLC) have improved since the introduction of the first immunotherapeutic in this population in the United States in 2015, according to a recent study published by Wang et al in Cancer. NSCLC accounts for up to 90% of all...
FDA Approves IDH1/2 Inhibitor for Certain Patients With Astrocytoma or Oligodendroglioma
The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo), an isocitrate dehydrogenase-1 (IDH1) and -2 (IDH2) inhibitor, for adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following...
Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer
Nasopharyngeal carcinoma is a rare and aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than 1 per 100,000 in Europe, the United States, and the Pacific, data from the International...
Active Surveillance May Enable Patients With Esophageal Cancer to Delay or Avoid Surgery
Although esophageal cancer in the United States is relatively rare—affecting about 22,400 people each year and making up about 1% of all cancer cases—the disease is common in East and Central Asian countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous cell ...
EGFR-Mutated NSCLC: Tepotinib/Osimertinib in Patients With MET Amplification
In the phase II INSIGHT 2 trial reported in The Lancet Oncology, Yi-Long Wu, MD, and colleagues found that the combination of tepotinib plus osimertinib showed clinically meaningful activity in patients with advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) with MET...
Sacituzumab Govitecan in Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Alessandro D. Santin, MD, and colleagues, findings in the endometrial cancer cohort of the phase II multicohort TROPiCS-03 trial indicated activity of the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy in pretreated patients...
Common Blood Tests May Improve Early Cancer Diagnosis
The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...
FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma
On August 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have ...
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly With Chemotherapy
On August 1, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adults with primary advanced or recurrent endometrial cancer. Dostarlimab was previously approved in July 2023 with carboplatin...
Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?
Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bellinzona and the Università della Svizzera Italiana in Lugano. “Aggressive therapy is not needed in...
Ponatinib and Blinatumomab in Newly Diagnosed Ph-Positive ALL
In an updated analysis of a single-center phase II trial reported in the Journal of Clinical Oncology, Hagop Kantarjian, MD, and colleagues found that the simultaneous combination of ponatinib and blinatumomab continued to be associated with good outcomes in newly diagnosed patients with...
